SYSTEMIC ADMINISTRATION OF AN INHIBITOR OF ENDOTHELIN-CONVERTING ENZYME FOR ATTENUATION OF CEREBRAL VASOSPASM FOLLOWING EXPERIMENTAL SUBARACHNOID HEMORRHAGE
Hh. Caner et al., SYSTEMIC ADMINISTRATION OF AN INHIBITOR OF ENDOTHELIN-CONVERTING ENZYME FOR ATTENUATION OF CEREBRAL VASOSPASM FOLLOWING EXPERIMENTAL SUBARACHNOID HEMORRHAGE, Journal of neurosurgery, 85(5), 1996, pp. 917-922
The potent vasoconstrictor peptide, endothelin-1 (ET-1), has been impl
icated in the pathophysiology of cerebral vasospasm that occurs after
subarachnoid hemorrhage (SAH). This peptide is synthesized as a large
prepropeptide that requires a series of modifying steps for its activa
tion. The last of these steps involves the proteolytic conversion of a
relatively inactive propeptide, Big ET-1. to its active, 21-amino aci
d peptide form. The enzyme responsible for converting Big ET-1 to ET-1
is a metalloprotease called endothelin-converting enzyme (ECE). In th
e present study the authors examined the effects of a newly developed
inhibitor of ECE on responses to ET peptides in the normal basilar art
ery and on pathophysiological constriction in the spastic basilar arte
ry after SAH. In the first series of experiments the authors examined
normal basilar arteries in the rabbit, which were exposed transclivall
y and measured on-line using videomicroscopy. Intravenous administrati
on or topical application of an active inhibitor of ECE, CGS 26303, bl
ocked vasoconstrictor responses to topically applied Big ET-1 but not
to ET-1. In contrast, topical application of a structurally related co
mpound that does not inhibit ECE, CGS 24592, was ineffective in blocki
ng vasoconstriction that was elicited by a topical application of Big
ET-1. These findings indicate that CGS 26303 when administered systemi
cally is capable of blocking the conversion of Big ET-1 to ET-1 in the
basilar artery without affecting the ability of the vessel to respond
to ET-1. In the second series of experiments the authors examined the
effects of the ECE inhibitor on cerebral vasospasm after experimental
SAH. Intraperitoneal administration of CGS 26303 via osmotic minipump
s significantly attenuated the delayed spastic response of the basilar
artery to an intracisternal injection of autologous blood. This study
provides the first evidence that systemic administration of an inhibi
tor of ECE is capable of preventing cerebral vasospasm after SAH. The
results reinforce a growing body of evidence that ETs play a critical
role in the development of spastic constriction after SAH. Moreover, t
he findings indicate that blocking the conversion of Big ET-1 to its a
ctive ET-1 form using CGS 26303 may represent a feasible strategy for
ameliorating cerebral vasospasm.